Hypercholesterolemia is common after pediatric heart transplantation: Initial experience with pravastatin

Journal of Heart and Lung Transplantation

Volumn 23, Issue 3, 2004, Pages 317-322

  Seipelt, Ingrid M ^a   Crawford, Susan E ^a   Rodgers, Sherrie ^a   Backer, Carl ^a   Mavroudis, Constantine ^a   Seipelt, Ralf G ^a   Pahl, Elfriede ^a  

^a CHILDREN'S MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CREATINE KINASE; CYCLOSPORIN; LIVER ENZYME; LOW DENSITY LIPOPROTEIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHOSPHOTRANSFERASE; PRAVASTATIN; PREDNISONE; TACROLIMUS;

ADOLESCENT; CARDIAC ALLOGRAFT VASCULOPATHY; CHILD; CHOLESTEROL BLOOD LEVEL; CONGENITAL HEART DISEASE; CONGESTIVE CARDIOMYOPATHY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFANT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MYALGIA; NAUSEA; PEDIATRIC SURGERY; PREVALENCE; PRIORITY JOURNAL; RECIPIENT; RESTRICTIVE CARDIOMYOPATHY; REVIEW; SYMPTOMATOLOGY; VASCULAR DISEASE; VOMITING;

EID: 1542408618     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-2498(03)00193-1     Document Type: Article

References (30)

1. Ballantyne C.M., Radovancevic R., Farmer J.A., et al. Hyperlipidemia after heart transplantation report of a 6-year experience, with treatment recommendations. J Am Coll Cardiol. 19:(6):1992;1315-1321.
2. Winters G., Kendall T., Radio S., et al. Posttransplant obesity and hyperlipidemia major predictors of severity of coronary arteriopathy in failed human heart allografts. J Heart Transplant. 9:1990;364-371.
3. Ibels L., Alfrey A., Weil R. Hyperlipidemia in adult, pediatric and diabetic renal transplant recipients. Am J Med. 64:1978;634-642.
4. Schorn T.F., Kliem V., Bojanovski D.J., Clark W.F. Effect of cyclosporine A on serum lipids in stable renal transplant recipients. Transplant Int. 4:1991;92-95.
5. Arnadottir M., Thysell H., Nilsson-Ehle P. Lipoprotein levels and postheparin lipase activities in kidney transplant recipients. cyclosporine versus non-cyclosporine-treated patients. Am J Nephrol. 11:1991;391-396.
6. Luke D.R., Brunner L.J., Lopez-Berestein G., Yau J.C. Pharmacokinetics of cyclosporine in bone marrow transplantation longitudinal characterization of drug lipoprotein fractions. J Pharmacol Sci. 81:1992;208-211.
7. Ballantyne C.M., Podet E.J., Patsch W.P., et al. Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA. 262:1989;53-56.
8. Abouljoud M.S., Levy M.F., Klintmalm G.B., US Multicenter Study Group. Hyperlipidemia after liver transplantation long-term results of the FK506/cyclopsporine A US Multicenter Trial. Transplant Proc. 27:1995;1121-1123.
9. Becker D.M., Chamberlain B., Swank R., et al. Relationship between corticosteroid exposure and plasma lipid levels in heart transplant recipients. Am J Med. 85:1988;632-638.
10. Valantine H.A. Role of lipids in allograft vascular disease a multicenter study of intimal thickening detected by intravascular ultrasound. J Heart Lung Transplant. 14:1995;234-237.
11. Kobashigawa J.A., Katznelson S., Laks H., et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 333:1995;621-627.
12. Wenke K., Meiser B., Thiery J., et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation. Circulation. 96:1997;1398-1402.
13. Costanzo M.R., Naftel D.C., Pritzker M.R., et al. Heart transplant coronary artery disease detected by coronary angiography a multiinstitutional study of preoperative donor and recipient risk factors. Cardiac Transplant Research Database. J Heart Lung Transplant. 17:(8):1998;744-753.
14. Pahl E., Zales V.R., Fricker F.J., Addonizio L.J. Posttransplant coronary artery disease in children. A Multicenter National Survey. Circulation. 90:(2):1994;56-60.
15. Hess M.L., Hastillo A., Mohanakumar T., et al. Accelerated atherosclerosis in cardiac transplantation role of cytotoxic B-cell antibodies and hyperlipidemia. Circulation. 68:(suppl2):1983;94-101.
16. Valantine-von Kaeppler H.A. Do calcium channel blockers and HMG-CoA reductase inhibitors attenuate allograft arteriopathy? Curr Opin Cardiol. 13:1998;111-116.
17. Uretsky B.F., Murali S., Reddy P.S. Development of coronary artery disease in cardiac transplant recipients receiving immunosuppressive therapy with cyclosporine and prednisone. Circulation. 76:1987;827-834.
18. Rickenbacher P.R., Kemna M.S., Pinto F.J., et al. Coronary artery intimal thickening in the transplanted heart. An in vivo intracoronary ultrasound study of immunologic and metabolic risk factors. Transplantation. 61:1996;46-53.
19. Valantine H., Rickenbacher R., Kemna M.S., et al. Metabolic abnormalities characteristic of syndrome X predict long outcome in heart transplant recipients (abstract). J Heart Lung Transplant. 14:1995;S58.
20. McManus B.M., Horley K.J., Wilson J.E., et al. Prominence of coronary arterial wall lipids in human heart allografts. Am J Pathol. 147:1995;293-308.
21. Jaeger B.R., Meiser B., Nagel D., et al. Aggressive lowering of fibrinogen and cholesterol in the prevention of graft vessel disease after heart transplantation. Circulation. 96:(suppl2):1997;154-158.
22. Eich D., Thomson J.A., Ko D., et al. Hypercholesterolemia in long-term survivors of heart transplantation an early marker of accelerated coronary artery disease. J Heart Lung Transplant. 10:1991;45-49.
23. Chin C., Rosenthal D., Bernstein D. Lipoprotein abnormalities are highly prevalent in pediatric heart transplant recipients. Pediatr Transplant. 4:(3):2000;193-199.
24. Gadbut A., Caruso A., Galper J. Differential sensitivity of C2-C12 striated muscle cells to lovastatin and pravastatin. J Mol Cell Cardiol. 27:1995;2397-2402.
25. Christians U., Jacobsen W., Floren L.C. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients are the statins mechanistically similar? Pharmacol Ther. 80:1998;1-37.
26. Penson M.G., Fricker F.J., Thompson J.R., et al. Safety and efficacy of pravastatin therapy for the prevention of hyperlipidemia in pediatric and adolescent cardiac transplant recipients. J Heart Lung Transplant. 20:(6):2001;611-618.
27. Ballantyne C.M., Bourge R.C., Domalik L.J., et al. Treatment of hyperlipidemia after heart transplantation and rationale for the Heart Transplant Lipid Registry. Am J Cardiol. 78:1996;532-535.
28. Lipid Research Clinics Population Studies Data Book, Vol I: The Prevalence Study, US Department of Health and Human Services, National Institutes of Health Publication No. 80-1527. Government Printing Office, July 1980
29. Corpier C.L., Jones P.H., Suki W.N., et al. Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients. JAMA. 260:1988;239-241.
30. Committee on Nutrition of the American Academy of Pediatrics. Cholesterol in Childhood. Pediatrics. 101:(1):1998;141-147.